Show simple item record

dc.contributor.authorStein, Robert Cen
dc.contributor.authorMakris, Andreasen
dc.contributor.authorHughes-Davies, Lukeen
dc.contributor.authorMacpherson, Iain Ren
dc.contributor.authorHall, Peter Sen
dc.contributor.authorCameron, David Aen
dc.contributor.authorEarl, Helenaen
dc.contributor.authorPinder, Sarah Een
dc.contributor.authorPoole, Christopher Jen
dc.contributor.authorRea, Daniel Wen
dc.contributor.authorMcIntosh, Stuarten
dc.contributor.authorHarmer, Victoriaen
dc.contributor.authorMorgan, Adrienneen
dc.contributor.authorRooshenas, Leilaen
dc.contributor.authorConefrey, Carmelen
dc.contributor.authorDonovan, Jenny Len
dc.contributor.authorHulme, Claireen
dc.contributor.authorMcCabe, Christopheren
dc.contributor.authorStallard, Nigelen
dc.contributor.authorCampbell, Amyen
dc.contributor.authorHiggins, Helenen
dc.contributor.authorBartlett, John MSen
dc.contributor.authorMarshall, Andreaen
dc.contributor.authorDunn, Janet Aen
dc.date.accessioned2018-09-05T11:09:38Z
dc.date.available2018-09-05T11:09:38Z
dc.date.issued2018-02en
dc.identifier.issn0008-5472
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/279233
dc.description.abstractBackground: Multi-parameter gene expression assays (MPAs) are widely used to estimate individual patient residual risk in hormone-sensitive HER2-negative node-negative early breast cancer, allowing patients with low risk to safely avoid chemotherapy. Evidence for MPA use in node-positive breast cancer is limited. OPTIMA (Optimal Personalised Treatment of early breast cancer usIng Multi-parameter Analysis) aims to validate MPA’s as predictors of chemotherapy sensitivity in a largely node-positive breast cancer population.
dc.titleOPTIMA: A prospective randomized trial to validate the predictive utility and cost-effectiveness of gene expression test-directed chemotherapy decisions in early breast canceren
dc.typeConference Object
prism.issueIdentifier4en
prism.publicationDate2018en
prism.publicationNameCANCER RESEARCHen
prism.volume78en
dc.identifier.doi10.17863/CAM.26613
dcterms.dateAccepted2017-08-25en
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserveden
rioxxterms.licenseref.startdate2018-02en
dc.contributor.orcidEarl, Helena [0000-0003-1549-8094]
dc.identifier.eissn1538-7445
rioxxterms.typeConference Paper/Proceeding/Abstracten
rioxxterms.freetoread.startdate2019-02-28


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record